A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.
Weight loss drugs may be the answer to slowing cancer progression and a lower risk of death, according to new research, which ...
A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...
ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate ...
(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...
Morning Overview on MSN
A daraxonrasib trial just held pancreatic cancer in check for 8.5 months in most patients — twice as long as standard chemo for tumors that spread after first-line tr…
Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...
NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...
Low testosterone may increase the risk of aggressive prostate cancer progression during active surveillance. Learn more about the findings.
(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results